https://www.selleckchem.com/pr....oducts/zanubrutini-b
Significant correlations of CTRCD included treatment with trastuzumab (P = 0.001) or pertuzumab (P 0.001), lower baseline global longitudinal strain (GLS) (P = 0.016), increased left ventricular end systolic diameter (P 0.001), and lower e' septal (P 0.001). CTRCD is an important concern among patients with active breast cancer, regardless of baseline risk factors, and is associated with trastuzumab and pertuzumab treatment. Early GLS evaluation may contribute to risk stratification and allow deployment of ca
Like
Comment
Share
